Loading stock data…
DexCom, Inc. (DXCM)
$69.98-0.16 (-0.23%)
Market ClosedLast close Jun 29
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
DexCom, Inc. in the Healthcare sector is trading at $69.98 with a market capitalization of $28.1B. Wall Street consensus targets $85.24 (25 analysts), implying a +21.8% move over the next 12 months. The stock is currently 22% below its 52-week high of $89.98, remaining 4.1% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +21.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 32) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.19B↓ | $1.26B↑ | $1.21B↑ | $1.16B↑ | $1.04B |
| Gross Profit | $750.30M↓ | $792.70M↑ | $731.40M↑ | $688.80M↑ | $589.00M |
| Operating Income | $255.30M↓ | $323.00M↑ | $242.50M↑ | $212.60M↑ | $133.70M |
| Net Income | $199.50M↓ | $267.30M↓ | $283.80M↑ | $179.80M↑ | $105.40M |
Peer Comparison
JNJUNHPFE
Fundamentals
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$28.08B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
31.23
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
31.47%
Volume
Today's trading volume
3.64M
Recent News
DexCom, Inc. (DXCM) Further Advances Vision of Glucose Biosensing for All
DexCom, Inc. (NASDAQ:DXCM) is among the Best Healthcare Stocks. On June 23, DexCom, Inc. (NASDAQ:DXCM) announced that the FDA cleared growing use of its Stelo Glucose Biosensor beyond adults for children ages 2 and older who do not use insulin. President and CEO Jake Leach said, “Glucose matters for everyone.” The company plans to broaden access […]
DexCom (DXCM) Stock After Three-Year 45% Slide Is The Market Too Pessimistic
If you are wondering whether DexCom stock still offers value after a choppy few years, this article walks through what the current price could be implying about future expectations. At a last close of US$70.14, DexCom is up 5.4% year to date, yet the stock is still down 18.8% over the past year and 45.4% over three years. This may leave investors questioning whether sentiment or fundamentals are doing more of the work. Recent coverage has focused on DexCom's role in glucose monitoring...
Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now?
DXCM outpaces Abbott with expanding CGM access, new product launches and broader coverage, making it the stronger stock to watch now.
Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Buy
Abbott Laboratories (NYSE:ABT) at $90.53 is a Buy. The healthcare giant has been swept up in a sector-wide rotation out of defensive names, even as its diabetes franchise compounds and its medical devices unit posts double-digit growth. Abbott spans medical devices, diagnostics, established pharmaceuticals, and nutrition, with Robert B. Ford as CEO. FreeStyle Libre, the ... Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Bu
DexCom to Roll Out Reimagined Stelo App With Global Expansion Plans
DXCM's redesigned Stelo app is set for a July U.S. rollout, with international expansion and pediatric clearance broadening its glucose insights push.